Table 3 Efficacy evaluation according to tumor type*
From: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Variable | Gastric n = 28 | Other n = 9 | All n = 37 |
|---|---|---|---|
Best overall response | |||
CR, n (%) | 0 | 0 | 0 |
PR, n (%) | 16 (57.1) | 2 (22.2) | 18 (48.6) |
SD, n (%) | 5 (17.9) | 4 (44.4) | 9 (24.3) |
PD, n (%) | 7 (25.0) | 3 (33.3) | 10 (27.0) |
ORR, n (%) [95% CI] | 16 (57.1) [37.2, 75.5] | 2 (22.2) [2.8, 60.0] | 18 (48.6) [31.9, 65.6] |
DCR, n (%) [95% CI] | 21 (75.0) [55.1, 89.3] | 6 (66.7) [29.9, 92.5] | 27 (73.0) [55.9, 86.2] |
mPFS (months) [95% CI] | 4.2 [3.7, 9.2] | 2.6 [1.8, 3.5] | 3.7 [2.6, 5.4] |
6-month OS rate (%) [95% CI] | 81.2 [60.3, 91.8] | 77.8 [36.5, 93.9] | 80.1 [62.5, 90.0] |
6-month DOR rate (%) [95% CI] | 53.3 [20.7, 77.8] | NA | 44.8 [17.3, 69.3] |
